Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 11/2009

01-11-2009 | SSAT Poster Presentation

Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma

Authors: Joshua G. Barton, John P. Bois, Michael G. Sarr, Christina M. Wood, Rui Qin, Kristine M. Thomsen, Michael L. Kendrick, Michael B. Farnell

Published in: Journal of Gastrointestinal Surgery | Issue 11/2009

Login to get access

Abstract

Background

Preoperative serum values of CA 19-9 have been reported to be associated with survival in patients undergoing resection of pancreatic adenocarcinoma.

Hypothesis

Preoperative CA 19-9 levels are associated with margin and/or lymph node status in patients undergoing pancreatoduodenectomy for pancreatic carcinoma.

Methods

We conducted a review of 143 patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma from July 2001 through April 2006 at our institution. Preoperative serum values of CA 19-9 and total bilirubin, pathologic findings, and survival were analyzed. A cutoff value for CA 19-9 (120 U/ml) was determined using a Cox proportional hazards model for survival.

Results

Overall survival at 1, 3, and 5 years for patients with CA 19-9 ≤ 120 U/ml was 76%, 41%, and 31%, respectively, versus 64%, 17%, and 10% for patients with CA 19-9 > 120 U/ml (p = 0.002). CA 19-9 > 120 U/ml was not associated, however, with a greater chance of an R1 or R2 resection (p = 0.86), tumor involving the SMA margin (p = 0.88), tumor at the portal vein groove (p = 0.14), or lymph node metastases (p = 0.89).

Conclusions

Our findings do not support a cutoff value for CA 19-9 that is associated with margin or lymph node involvement. Preoperative CA 19-9 ≤ 120 U/ml is, however, associated with increased overall and recurrence-free survival.
Literature
1.
5.
go back to reference Montgomery RC, Hoffman JP, Riley LB, Rogatko A, Ridge JA, Eisenberg BL. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol 1997;4:551–556. doi:10.1007/BF02305535.CrossRefPubMed Montgomery RC, Hoffman JP, Riley LB, Rogatko A, Ridge JA, Eisenberg BL. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol 1997;4:551–556. doi:10.​1007/​BF02305535.CrossRefPubMed
6.
go back to reference Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;24:2897–2902. doi:10.1200/JCO.2005.05.3934.CrossRefPubMed Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;24:2897–2902. doi:10.​1200/​JCO.​2005.​05.​3934.CrossRefPubMed
9.
go back to reference Safi F, Schlosser W, Falkenreck S, Beger HG. Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology 1998;45:253–259.PubMed Safi F, Schlosser W, Falkenreck S, Beger HG. Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology 1998;45:253–259.PubMed
13.
go back to reference LexisNexis. Accurint®, a LexisNexis® commercial location and research online service. Philadelphia, PA: LexisNexis, 2008. LexisNexis. Accurint®, a LexisNexis® commercial location and research online service. Philadelphia, PA: LexisNexis, 2008.
14.
go back to reference Contal C, O’Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal 1999;30:253–270.CrossRef Contal C, O’Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal 1999;30:253–270.CrossRef
18.
go back to reference Temudom T, Sarr MG, Douglas MG, Farnell MB. An argument against routine percutaneous biopsy, ERCP, or biliary stent placement in patients with clinically resectable periampullary masses: a surgical perspective. Pancreas 1995;11:283–288. doi:10.1097/00006676-199510000-00011.CrossRefPubMed Temudom T, Sarr MG, Douglas MG, Farnell MB. An argument against routine percutaneous biopsy, ERCP, or biliary stent placement in patients with clinically resectable periampullary masses: a surgical perspective. Pancreas 1995;11:283–288. doi:10.​1097/​00006676-199510000-00011.CrossRefPubMed
Metadata
Title
Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma
Authors
Joshua G. Barton
John P. Bois
Michael G. Sarr
Christina M. Wood
Rui Qin
Kristine M. Thomsen
Michael L. Kendrick
Michael B. Farnell
Publication date
01-11-2009
Publisher
Springer-Verlag
Published in
Journal of Gastrointestinal Surgery / Issue 11/2009
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-009-0849-z

Other articles of this Issue 11/2009

Journal of Gastrointestinal Surgery 11/2009 Go to the issue